| Autor: |
Hicks KA; RTI Health Solutions, RTI International, Research Triangle Park, NC, USA., Ghaswalla P; Vaccines, GSK, Philadelphia, PA, USA., Carrico J; RTI Health Solutions, RTI International, Research Triangle Park, NC, USA., Anderson S; RTI Health Solutions, RTI International, Research Triangle Park, NC, USA., Novy P; Vaccines, GSK, Philadelphia, PA, USA., Hogea C; Vaccines, GSK, Philadelphia, PA, USA., Hayney MS; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA. |
| Abstrakt: |
Objective: We developed an Excel-based cost calculator to assess the economic burden of university-based Neisseria meningitidis serogroup B (MenB) outbreaks. Participants: Hypothetical university with 6,354 students. Methods: Total societal costs of outbreak were estimated for three MenB pre-matriculation immunization policies-vaccination required, vaccination recommended, and no vaccine policy-under three different cost assumptions (low/mid-range/high cost). Results: Mid-range cost estimates of an outbreak under "no policy" were $2.60 and $2.70 million (of which 35% were incurred by the university) if targeting all undergraduates for mass vaccination with a two-/three-dose vaccine, respectively. The "required" and "recommended" policies lowered the burden to $2.17-$2.18 million and $2.34-$2.39 million, respectively. For a larger university with 40,000 students, costs were almost $9 million for a two-dose vaccine with "no policy" in place. Conclusions: The economic burden of a university MenB outbreak is substantial, but could be mitigated by a pre-matriculation MenB vaccination requirement or recommendation. |
